Related Experiment Video
Updated: Jun 21, 2026
13:45
Real-time Imaging of Leukotriene B4 Mediated Cell Migration and BLT1 Interactions with β-arrestin
Published on: December 23, 2010
The leukotriene E4 puzzle: finding the missing pieces and revealing the pathobiologic implications
K Frank Austen1, Akiko Maekawa, Yoshihide Kanaoka
1Department of Medicine, Harvard Medical School, Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, Mass 02115, USA. fausten@rics.bwh.harvard.edu
The Journal of Allergy and Clinical Immunology
|August 4, 2009
Summary
Leukotriene E4 (LTE4) is a stable inflammatory mediator found in asthma. New research identifies distinct LTE4 receptors, offering novel therapeutic targets beyond current antagonists.
Area of Science:
- Immunology
- Pharmacology
- Biochemistry
Background:
- Cysteinyl leukotrienes (cysLTs) mediate allergic inflammation.
- Leukotriene E4 (LTE4) is the stable end-product of cysLT metabolism, found in biological fluids of asthmatics.
- LTE4 has been understudied due to poor binding to classical cysLT receptors (CysLT1/2).
Purpose of the Study:
- To investigate the underappreciated role of LTE4 in inflammation.
- To identify and characterize novel receptors for LTE4.
- To explore new therapeutic targets for inflammatory diseases.
Main Methods:
- Review of existing literature on cysLTs and LTE4.
- Analysis of studies investigating LTE4's effects on human and animal models.
- Identification of potential novel LTE4 receptors through recent research.
Main Results:
- LTE4 induces skin swelling comparably to LTC4 and LTD4.
- Asthmatic airways, especially aspirin-sensitive ones, show selective hyperresponsiveness to LTE4.
- Novel LTE4 receptors, including P2Y12 and CysLT(E)R, have been identified.
Conclusions:
- LTE4 plays a significant role in inflammatory responses.
- The identification of specific LTE4 receptors opens new avenues for therapeutic intervention.
- Targeting novel LTE4 receptors could offer a new strategy for treating inflammatory conditions like asthma.
More Related Videos
Related Concept Videos
01:19Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
01:28Asthma I: Introduction
Asthma is a chronic inflammatory disorder of the airways characterized by variable airflow obstruction and heightened bronchial responsiveness to a wide range of triggers. The underlying inflammation leads to airway swelling, mucus hypersecretion, and smooth muscle constriction, all of which narrow the airway lumen and impede airflow. Clinically, asthma presents with recurrent episodes of wheezing, shortness of breath, chest tightness, and coughing, symptoms that typically vary in intensity and...
01:20Asthma: Pathogenesis and Management
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
01:30Asthma-IV: Diagnostic and Management
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
01:26Asthma-II: Pathophysiology and Classification
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
01:26Acute Inflammation II: Cellular Phase
The cellular phase of acute inflammation is a tightly orchestrated sequence of events that recruits leukocytes, primarily neutrophils, to sites of tissue injury or infection. Following the initial vascular changes, this phase ensures effective immune cell migration, activation, and function at the affected site to eliminate pathogens and initiate tissue repair.Leukocyte Recruitment CascadeLeukocyte recruitment happens in four steps: margination, adhesion, transmigration, and chemotaxis. Reduced...